Results 181 to 190 of about 8,106 (209)
Some of the next articles are maybe not open access.
Drug Metabolism and Disposition, 2000
Ticlopidine is associated with a relatively high incidence of agranulocytosis and aplastic anemia. We have shown that other drugs associated with agranulocytosis are metabolized to reactive metabolites by activated human neutrophils or by HOCl, which is the major oxidant produced by activated neutrophils.
Z C, Liu, J P, Uetrecht
openaire +2 more sources
Ticlopidine is associated with a relatively high incidence of agranulocytosis and aplastic anemia. We have shown that other drugs associated with agranulocytosis are metabolized to reactive metabolites by activated human neutrophils or by HOCl, which is the major oxidant produced by activated neutrophils.
Z C, Liu, J P, Uetrecht
openaire +2 more sources
Journal of Neuroscience Nursing, 1992
Ticlopidine, a new prototype antiplatelet agent, offers a significant alternative in the primary and secondary prevention of atherothrombotic stroke. While 2 multicenter trials demonstrated benefits of ticlopidine, this drug is not without risks and limitations and more studies are indicated.
openaire +2 more sources
Ticlopidine, a new prototype antiplatelet agent, offers a significant alternative in the primary and secondary prevention of atherothrombotic stroke. While 2 multicenter trials demonstrated benefits of ticlopidine, this drug is not without risks and limitations and more studies are indicated.
openaire +2 more sources
VASOMODULATORY ACTION OF CLOPIDOGREL AND TICLOPIDINE
Thrombosis Research, 1997Clopidogrel is a thienopyridine derived antiplatelet drug that has currently undergone extensive clinical trials in the management of various arterial disorders related to platelet activation. While the proposed mechanism of its pharmacologic action is believed to be the inhibition of ADP mediated direct and indirect actions on platelet adhesion ...
Li Hui Yang, Jawed Fareed
openaire +3 more sources
Clinical Pharmacokinetics of Ticlopidine
Clinical Pharmacokinetics, 1994Platelets contribute significantly to arterial-occlusive thrombosis, one of the major causes of death and disease throughout the world. Consequently, inhibiting platelet function is a potentially important therapeutic goal. Among agents that inhibit platelet function, ticlopidine shows a wide spectrum of antiplatelet activity. There have been a limited
openaire +3 more sources
Ticlopidine-Induced Cholestatic Hepatitis
Annals of Pharmacotherapy, 2003OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases. CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission ...
Zev Sthoeger +3 more
openaire +3 more sources
Determination of Ticlopidine in Pharmaceutical Products
Analytical Letters, 2007Abstract The voltammetric behaviour of ticlopidine‐HCl was studied using square‐wave, sampled direct current and cyclic voltammetry. The drug showed a cathodic peak at −0.01V versus Ag/AgCl with hanging mercury drop electrode. The current was investigated using cyclic voltammetry and characterized as diffusion controlled.
Tuerkoez, Ebru, Onar, A. Nur
openaire +3 more sources
Ticlopidine and Stroke Prevention
Hospital Practice, 1993(1993). Ticlopidine and Stroke Prevention. Hospital Practice: Vol. 28, No. sup5, pp. 20-22.
openaire +3 more sources
Interaction of ticlopidine with the erythrocyte membrane
Biochemical Pharmacology, 1982The membrane effects of ticlopidine on the erythrocyte membrane were explored by the spin label method at the proteic and phospholipidic levels. This spectroscopic study was completed by polyacrylamide gel electrophoresis of proteins, measurement of the protection against haemolysis and observation of the erythrocyte shape changes induced by the drug ...
Magali Sablayrolles +3 more
openaire +3 more sources
Modulation of Vasoconstriction by Clopidogrel and Ticlopidine
Thrombosis Research, 1998Clopidogrel is an antiplatelet drug which has undergone extensive clinical trials in the management of stroke and other arterial disorders related to platelet activation. This agent is believed to produce the inhibition of ADP mediated direct and indirect actions leading to platelet adhesion/aggregation and other activation processes.
Debra Hoppensteadt +2 more
openaire +3 more sources
Overview of Ticlopidine’s Development
1993The discovery and development of a new molecule imply the interplay of chance, audacity, and challenge, as well as lessons from failures and difficulties in reaching scientific and medical recognition of therapeutic progress. Persistent efforts and a consistent preclinical and clinical program should sustain the 10- to 15-year endeavor needed for ...
Edouard Panak, Monique Verry
openaire +2 more sources